New drug combo tested for tough cancers, but study halted early

NCT ID NCT03522142

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested an experimental drug called INCB081776, alone or with an immunotherapy (retifanlimab), in 83 adults with advanced solid tumors like lung, kidney, or melanoma cancer. The goal was to check safety and find the right dose. However, the study was terminated early, so the full picture is unclear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INCB081776 (an experimental drug) and retifanlimab (an immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This was an early Phase 1 trial, so safety and dosing were still being figured out. The study was terminated early, so results are limited and may not lead to a usable treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Erasmus Medical Center

Rotterdam, 3015 GD, Netherlands
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Haukeland University Hospital

Bergen, 05021, Norway
Karolinska University Hospital Solna

Stockholm, 171 76, Sweden
Md Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis

Amsterdam, 1066 CX, Netherlands
Odense University Hospital

Odense C, 05000, Denmark
Rigshospitalet Uni of Hospital of Copenhagen

Copenhagen, 02100, Denmark
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Skane University Hospital Lund

Lund, 22185, Sweden
University Medical Center Groningen

Groningen, 9713GZ, Netherlands
University of Pennsylvania Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh

Pittsburgh, Pennsylvania, 15232, United States
University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States
Utprøvingsenheten, Oslo University Hospital Radiumhospitalet

Oslo, 00379, Norway
Yale Cancer Center

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.